Madrona Ventures Invests in Vilya to Develop AI-Designed Macrocycle Drugs Using IPD Tools

Madrona announces its investment in Vilya, which uses AI and computational protein design tools from David Baker’s Institute for Protein Design to generate novel macrocycle drugs that aim to combine oral dosing and high bioavailability with large binding surfaces to target diseases like cancer, inflammation, and neurodegeneration.

CChris Picardo DDavid Baker UUniversity of Washington